Behavioral effects of Ginkgo biloba L., Panax ginseng C.A. Mey. and Gincosan.

The behavioral effects of a standardized extract from Panax ginseng roots (G115), of a standardized extract from Ginkgo biloba leaves (GK501) and of their combination (PHL-00701) (Gincosan) were examined in experiments on rats with undisturbed memory and on rats with experimentally-impaired memory (by alcohol or by muscarinic- and dopamine-receptor antagonists), using methods for active avoidance (shuttle-box) and passive avoidance (step-down and step-through). On multiple administration G115, GK501 and PHL-00701 exerted favorable effects on learning and memory. These effects varied with the dose and administration schedules, with the rat strain and with the behavioral method. Based on earlier results, we discuss the role of changes in brain biogenic amines induced by the extracts in their mechanism of action. The present results allow for ranking G115, GK501 and their combination PHL-00701 (Gincosan) among cognition-enhancing (nootropic) drugs.

Effect of Ginkgo biloba extract on beta-adrenergic receptors in different rat brain regions.

The effect of oral administration of Ginkgo biloba extract at a dose of 90 mg/kg for 7 consecutive days on rat brain beta-adrenergic receptors in the frontal cortex, hippocampus, striatum and hypothalamus was studied. Ginkgo biloba treatment induced a significant decrease in the density (B(max)) of beta-adrenoreceptors in the frontal cortex and hippocampus. It has been suggested that modulation of the beta-adrenergic system is implicated in the favourable effects of Ginkgo biloba extracts on learning and memory.

Memory effects of the Ca2+ and 5-HT antagonists dotarizine and flunarizine.

In experiments on Wistar and Long Evans rats, using behavioral methods for passive (step-down and step-through) and active (shuttle-box two-way avoidance with punishment reinforcement) the newly synthesized diphenyl-methyl-piperazine derivative with Ca2+ and 5-HT antagonistic action dotarizine (DOT) administered repeatedly at oral doses of 50 and 10 mg/kg in some cases improve memory process. Under the same experimental conditions the chemically related to dotarizine Ca2+ antagonist flunarizine significantly facilitated retention. In old (Long Evans and Wistar) rats DOT in large dose decreases values of learning criterion. Probably this is a manifestation of the inherent to drugs with nootropic action "therapeutic window". Earlier investigations of the same and other authors suggest the participation of serotonergic neurotransmission in the mechanism of the memory effects of the drug DOT.

Fetal alcohol effects in rats exposed pre- and postnatally to a low dose of ethanol.

Wistar rats were exposed pre- and/or postnatally to a low dose of ethanol (1 g/kg of body weight of dams/day) via maternal peroral intubation. This dose significantly increased the mortality rate (23 to 32% vs. 7% in controls) in offspring exposed to ethanol during pregnancy, with a continued postnatal exposure having no additional effect. However, offspring cross-fostered to dams that had been exposed to ethanol only during gestation (the offspring themselves never being directly exposed to ethanol) displayed an even greater (59%) mortality. Growth of the offspring was initially delayed, but 9 weeks after birth their body weight reached that of the controls. The two-way active avoidance test showed an impairment, compared with the controls, of learning and memory in both male and female adolescent (9-week-old) rats, as well as in male (but not in female) 5-month-old rats born of dams exposed to ethanol during gestation and lactation. In the group of male rats treated prenatally and postnatally with ethanol, 60% were "poor learners," compared with 33% in the control group. Results suggest that ethanol at a dose of 1 g/kg/day administered to dams during gestation and lactation produced growth and behavioral changes in the offspring.

Does nitric oxide participate in the mechanism of action of dotarizine?

Behavioral and nociceptive effects of dotarizine (DOT) and other substances acting on migrainous attacks and nitric oxide (NO) metabolism were studied in comparative experiments on rats. Behavioral effects were evaluated by the changes induced in ambulations and rearings of rats in the Opto-Varimex apparatus; effects on nociception were determined by the changes of pain threshold in growing mechanical pressure on one of the rat paw. The data showed that (1) NO did not participate directly in the mechanism of the behavioral actions of DOT. A role could be ascribed to the modulating influence of DOT on the changes in NO formation induced by other agents; (2) the NO system did not participate in the mechanisms of the responses to the painful mechanical pressure on the rat paw; (3) the behavioral effects of the substances with facilitating or inhibitory action on the migrainous process (m-CPP and ergotamine) and the influence of substances proved to affect NO formation (L-arginine, histamine, L-NAME) on these effects suggest a role for NO as a modulating but not a basic factor in the mechanisms of action of these pro- and antimigrainous substances; and (4) the behavioral effects of DOT were similar to the effects of the antimigrainous drug ergotamine and different from the promigrainous drug meta-chlorophenyl-piperazine (m-CPP)--which suggest an antimigrainous activity of dotarizine.

Behavorial responses to the 5-HT1A receptor antagonist NAN190 injected into rat CA1 hippocampal area.

1. Behavioral responses to unilateral and bilateral microinjections of the 5-HT1A receptor antagonist, NAN190 [1-(2-methoxyphenyl)-4-[4-(2-phthalimido) butyl]piperazine hydrobromide] (1 microgram), into the hippocampal CA1 area of male Wistar rats were studied. 2. NAN190 decreased locomotor activity (the number of horizontal and vertical movements). The effect was most pronounced with microinjections of NAN190 into the right hippocampus. 3. Microinjections of NAN190 facilitated learning and memory in shuttle-box testing. 4. Microinjections of NAN190 had an anxiogenic effect in elevated plus-maze experiments and Vogel's conflict test. 5. The different behavioral responses to left and right microinjections of NAN190 in some of the behavioral tests suggest functional asymmetry of 5-HT1A receptors in the CA1 hippocampal area.

Effects on nociception of the Ca2+ and 5-HT antagonist dotarizine and other 5-HT receptor agonists and antagonists.

The effects of the Ca2+ and 5-HT1 and 5-HT2 receptor antagonist dotarizine and of some other agonists and antagonists of different 5-HT receptor subtypes administered alone or in combination with the 5-HT uptake inhibitor fluoxetine (FLU) on nociception were studied, using a foot-pressure method (analgesy-meter testing). Dotarizine (DOT) administered at a dose of 50 mg/kg for 3 days orally significantly increased the pain threshold. Fluoxetine (FLU) administered at a dose of 10 mg/kg for 3 days also significantly increased the pain threshold. The combination of DOT and FLU abolished the analgesic effects of the two drugs. The 5-HT1A and 5-HT1B/1C receptor agonists buspirone and m-CPP decreased the pain threshold. The antagonists of 5-HT1A(NAN-190),5-HT1/5-HT2(methysergide), 5-HT2 (ritanserin), and 5-HT3 (ondansetron) receptors as well as the agonists of 5-HT2(DOI) and 5-HT3 (mCPBG) receptors increased the pain threshold. Fluoxetine at a single dose of 10 mg/kg differently influenced the effects of the 5-HT agonists and antagonists on nociception. Comparison of the effects of dotarizine with the effects of some of the agonists and antagonists of 5-HT receptor subtypes on the nociceptive and other actions suggests the possibility of a therapeutic value of dotarizine as an antimigraine drug.

Behavioral effects of the cyclic cholecystokinin peptide analogue JMV-320.

The in vivo effects of JMV-320 (a highly selective CCKB receptor ligand) and of CCK-4 on exploratory activity and memory in rats were compared. JMV-320 and CCK-4 did not modulate exploratory activity in an open field test but decreased it in an elevated plus-maze. CCK-4 (50 micrograms/kg) impaired passive avoidance response 3 h after training and JMV-320 (1 and 10 micrograms/kg) decreased active avoidance response 24 h after training. The behavioral effects of JMV-320 resemble the effects of CCK-4 and suggest that in vivo JMV-320 acts as a CCKB receptor agonist.

Behavioural effects of two cholecystokinin analogues: JMV 236 and JMV 179.

The behavioural effects of two cholecystokinin analogues Boc-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2 (JMV 236), a potent CCK agonist, and Boc-Tyr(SO3H)-Nle-Gly-DTrp-Nle-Asp-2-Phenylethylester (JMV 179), a CCK antagonist were studied. JMV 236 (3.125, 12.5 and 50 micrograms/kg i.p.) dose-dependently decreased the exploratory activity of rats, the effect being significant for horizontal activity (ambulation) at doses of 12.5 and 50 micrograms/kg and for vertical activity (rearing) at a dose of 50 micrograms/kg. JMV 179 (3.125, 12.5 and 50 micrograms/kg i.p.) did not change the horizontal activity but dose-dependently decreased the vertical activity, the effect being significant at a dose of 50 micrograms/kg. JMV 236 administered immediately after training significantly facilitated short-term memory in passive avoidance situation but only tended to increase the mean latency upon retention testing on the 7th day. JMV 179 tended to increase the latency of the passive avoidance response upon retention testing at the 24th hour but not on the 7th day after training.

Asymmetry in behavioral responses to cholecystokinin microinjected into rat nucleus accumbens and amygdala.

The behavioral responses of rats to uni- or bilateral microinjections of the octapeptide cholecystokinin (CCK-8) into the left and/or right or both nucleus accumbens (NA) or amygdalae were studied. There were two main findings of effects of microinjections of CCK-8 into NA. First, bilateral injections of CCK-8 into NA dose-dependently decreased the horizontal activity. The second more important finding was that CCK-8 at a specific dose (0.01 micrograms) injected into the right NA increased the number of horizontal movements 6-fold as compared to the injection into the left NA. Neither uni- nor bilateral injections of CCK-8 into NA at all doses used induced changes in the vertical movements. CCK-8 injected into left, right or both amigdalae increased locomotion at the lowest dose (0.01 microgram), while at the high doses (0.5 and 1.0 microgram) it significantly decreased it. The plus-maze test confirmed the anxiogenic effect of CCK-8 (0.01 microgram) injected into amigdalae. CCK-8 exerted a favorable effect on learning and memory (shuttle-box) when injected into the left but not into the right amygdala. Injection of CCK-8 (0.01 micrograms) into left amygdala provoked a 4-fold increase of the number of avoidances as compared to the microinjection into the right amygdala.

Hippocampal asymmetry in the behavioral responses to the 5-HT1A receptor agonist 8-OH-DPAT.

The present study examined the behavioral responses of rats to unilateral and bilateral injections of the selective serotonin 1A (5-HT1A)-receptor agonist 8-hydroxydipropylaminotetralin hydrobromide (8-OH-DPAT) 1 microgram into the hippocampal CA1 area of male Wistar rats. 8-OH-DPAT increased locomotor activity, which was most pronounced with injections into the left hippocampus. The agonist impaired learning and memory (shuttle-box), especially when injected into the right hippocampus. The elevated plus-maze experiments showed that neither left nor right nor bilateral hippocampal injections of 8-OH-DPAT produced any anxiogenic effect. However, with Vogel's conflict test, right injections of 8-OH-DPAT produced anxiety. The present study has revealed hippocampal asymmetry in the behavioral responses to the 5-HT1A-receptor agonist 8-OH-DPAT.

Behavioral effects of the Ca2+/5-HT antagonist dotarizine.

The diphenyl-methyl-piperazine derivatives with Ca(2+)-antagonistic effect dotarizine (DOT), Fl-6020 and flunarizine were investigated in experiments on rats. The substances tested were administered repeatedly at an oral dose of 50 mg/kg. Behavioral methods were used to study the exploratory activity when the animals were placed in an environment that was unfamiliar to them (the chamber of the Opto Varimex apparatus), the elevated plus-maze method for examining the effect on anxiety, and the method of recording changes in motor activity (using the Automex II apparatus). DOT was found to increase motor activity and to have an anxiolytic effect. Combination of DOT--a compound with Ca(2+)--and 5-HT2-receptor antagonistic action--and the 5-HT-receptor agonists and antagonists used (buspirone, NAN190, pindolol, ritanserin and ondansetron) resulted in such changes in the development of habituation and in anxiety, which suggest that the modulating effects of DOT depend but partly on its typical interaction with the 5-HT2 receptor. Apparently, the Ca(2+)-antagonistic action of DOT plays a definite role, changing its biological activity depending on the 5-HT receptor subtype at the level of which the interaction is taking place.

Effects of cytidine diphosphate choline on rats with memory deficits.

The effects of cytidine diphosphate choline (CDP-choline, CAS 987-78-0) on learning and memory in rats with memory deficits were examined using behavioral methods of active avoidance with punishment reinforcement (shuttle-box), passive avoidance with punishment reinforcement (step-through and step-down), and active avoidance with positive (alimentary) reinforcement (staircase-maze). In the majority of experiments CDP-choline was applied orally at doses of 10-50 or 100 mg/kg daily for 7 days before the training session. The experiments were carried out on young-adult (aged 5 months) and old (aged 22 months) rats and on rats with a low capability for retention of learned behavior. Memory deficits were induced by the muscarinic cholinoceptor antagonist scopolamine (in young and old rats and mice), by the alpha 2-adrenoceptor agonist clonidine, by electroconvulsive shock, and by hypoxy. Memory deficits were also induced in rats offspring of dams that had been exposed to alcohol during pregnancy and lactation. The results suggest that CDP-choline acts as a memory-enhancing drug and that its effect is particularly pronounced in animals with memory deficits.

Memory effects of standardized extracts of Panax ginseng (G115), Ginkgo biloba (GK 501) and their combination Gincosan (PHL-00701).

In experiments on young (aged 3 months) and old (aged 26 months) rats, using some conditioned-reflex methods with punishment or positive reinforcement for active and passive avoidance (shuttle-box, step-down, step-through, and water maze), we studied the effects of the standardized extracts of Panax ginseng (G115), Ginkgo biloba (GK501) and their combination Gincosan (PHL-00701). The extracts were administered orally for 7 days before training at three increasing doses: 17, 50, and 150 mg/kg for G115; 10, 30, and 90 mg/kg for GK501; and 27, 80, and 240 mg/kg for PHL-00701. The two extracts and their combination improved the retention of learned behavior. This effect varied considerably with the extracts, with the dose and with the behavioral method used. The results suggest that the Panax ginseng G115 and the Ginkgo biloba GK501 extracts possess properties similar in every respect to those of nootropic drugs. The favorable effects on learning and memory of the combination of G115 plus GK501 and the other pharmacological activities inherent in the extracts characterize this combination, offered as Gincosan as a particularly promising drug in geriatric practice.

Effect of CDP-choline on learning and memory processes in rodents.

The effects of cytidine (5') diphosphocholine (CDP-choline) on learning and memory were studied using conditioned reflex methods for passive avoidance and active avoidance with punishment reinforcement (step-through, step-down, shuttle box and maze), for active avoidance with alimentary reinforcement (staircase maze), and the Morris water maze. The majority of experiments involved comparative studies of the nootropic drugs meclofenoxate and/or piracetam. CDP-choline was administered orally, in some of the experiments also intraperitoneally, at doses of 10-500 mg/kg body weight once or twice daily for 5 or 7 days. In separate cases only single doses were administered. Trainings started one hour after the last dose of the drugs. Retention tests were given 3 h, 24 h, 7 days or 10 days after training. The results obtained with the different methods document CDP-choline's ability to improve learning and memory in rats and mice. No essential differences in the effects of CDP-choline were established upon oral and intraperitoneal administration of the drug. The learning- and memory-facilitating effects of CDP-choline were similar to those of meclofenoxate and piracetam. The results of the present study permit us to define CDP-choline as a substance capable of improving cognitive levels.

[Lipid peroxidation changes in the brain in fetal alcohol syndrome]. / Izmeneniia perekisnogo okisleniia lipidov v mozge pri fetal'nom alkogol'nom sindrome.

The study was performed upon three groups of 12-week-old male rats. The first group of rats received ethanol/9 g/kg/day as 6% aqueous solution/during pregnancy and lactation, the second group received ethanol only during lactation and the third group, controls, received equicaloric sucrose solution. The concentrations of LPO products were determined in the homogenates of tissue from frontal cortex, striatum, hypothalamus, hippocamp and cerebellum. The concentration of fluorescent products in the brain structures of rats treated perinatally with ethanol was several-fold increased as compared with controls. The levels of diene conjugates were increased in most brain structures of rats with FAS. It should be pointed out that there was the same degree of increase of the levels of both fluorescent products and diene conjugates in two groups of rats with FAS. Having in mind that in the rat the increased growth of the brain occurs during the first 10 postnatal days, it might be assumed that this period is favorable for LPO.

Age-related changes in central and peripheral benzodiazepine binding sites.

3H-flunitrazepam binding was studied in membranes from different brain regions and from kidneys and adrenals of young (5-month old) and aged (22-month old) rats. Decreased benzodiazepine receptor density (by 33.7%) was observed only in the cerebellum of aged rats. The number of benzodiazepine receptors was significantly increased in the hypothalamus (by 44.1%). Specific 3H-flunitrazepam binding was also significantly increased in both kidney and adrenal membranes from old rats.

Learning and memory in rats exposed pre- and postnatally to alcohol. An attempt at pharmacological control.

Using conditioned-reflex methods for active and passive avoidance with punishment reinforcement, we found pronounced memory deficits in 12-week old rats exposed perinatally to alcohol (FAS rats). Impairment of memory was observed not only with the high dose of 9 g ethanol/kg body weight (ingested with tap water in a 6% solution) to which dams were exposed during pregnancy and lactation, but also with the ten-fold lower dose of 1 g ethanol/kg body weight (0.6% ethanol). The nootropic drugs citicholine, piracetam and meclofenoxate administered orally for five days before the training session were effective in decreasing memory deficits; particularly pronounced was the effect of piracetam and meclofenoxate. The benzodiazepine tranquilizer diazepam additionally impaired learning and memory in FAS rats. It is suggested that nootropics could be used to decrease the cognitive disturbances in some humans born to alcoholic mothers.

Age-related changes of the effects of a group of nootropic drugs on the content of rat brain biogenic monoamines.

1. The changes in the levels of brain biogenic monoamines (BMAs) after chronic (7 days) treatment with piracetam, aniracetam and structural analogues of aniracetam (p-H, p-F, p-Cl, p-P and m-D) were studied in young and old rats. 2. An age-related significant decrease in the BMA content was established in old rats. 3. Most of the investigated compounds increased the level of one or other BMA in one or other of the brain structures studied. This elevation was predominantly established in old rats. 4. The present results and those from previous behaviour studies show that elevation of one or more of the BMA levels in one or more brain regions plays a beneficial role in the realization of their effects on the processes of learning and memory.

Caerulein receptors on the cholinergic neurons in guinea-pig ileum.

The release of [3H]ACh and the contractions of guinea-pig ileal longitudinal muscle preparations, with myenteric plexus attached were measured and recorded simultaneously. Caerulein in concentrations of 10(-11) M to 10(-8) M caused dose-dependent increase of the contractions and the [3H]ACh release. This excitatory effect of caerulein was sensitive to TTX (10(-6) M). Proglumide selectively antagonized both the contractions and the [3H]ACh-releasing effect of caerulein. Electrical field stimulation (O.1 Hz)-evoked contractions were sensitive to atropine. Caerulein (10(-9) M) did not influence the electrically-evoked release of [3H]ACh and the electrically-evoked contractions. Nifedipine (10(-6)M) decreased them about 50%. In the presence of nifedipine caerulein produced an inhibitory effect on the electrically-induced contractions. This nifedipine-unmasking inhibitory effect of caerulein was accompanied by a decrease of the [3H]ACh release and was prevented by proglumide.